1. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Issue 1 (27th October 2014) Authors: Khanna, R.; Zou, G.; D'Haens, G.; Feagan, B. G.; Sandborn, W. J.; Vandervoort, M. K.; Rolleri, R. L.; Bortey, E.; Paterson, C.; Forbes, W. P.; Levesque, B. G. Journal: Alimentary pharmacology & therapeutics Issue: Volume 41:Issue 1(2015) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Issue 1 (22nd October 2014) Authors: Bajaj, J. S.; Barrett, A. C.; Bortey, E.; Paterson, C.; Forbes, W. P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 41:Issue 1(2015) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials. Issue 10 (3rd April 2014) Authors: Schoenfeld, P.; Pimentel, M.; Chang, L.; Lembo, A.; Chey, W. D.; Yu, J.; Paterson, C.; Bortey, E.; Forbes, W. P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 39:Issue 10(2014) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗